Skip to content
DataLookout
Menu

NCT07622329

A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

StatusRecruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Study completion moved earlier from Jun 30, 2027 to Dec 30, 2026
    • Primary completion date changed from estimate of Aug 30, 2026 to Sep 2, 2026
    • Secondary endpoints: details revised at 5 of 11 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and tolerability of JCXH-213
Timeframe: The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).

Secondary (11)

Platelet count over time
Time to platelet response
Cumulative weeks of platelet response
Change in WHO bleeding score
Degree of disease control
Show 6 moreShow less
Changes in platelet autoantibodies
Peripheral blood B-cell subset profiling
Changes in peripheral blood JCXH-213 mRNA levels
Changes in peripheral blood CD19 CAR-positive cells
Changes in peripheral blood cytokine levels
Changes in anti-drug antibodies (ADA)

Arms and interventions

Dose Level (2 mg,4 mg)Experimental

Drugs: JCXH-213

Sites

1 site in 1 country

  • General Hospital of Western Theater Command of PLAChengdu, Chengdu, China